K. Huber

7.4k total citations · 1 hit paper
60 papers, 3.0k citations indexed

About

K. Huber is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, K. Huber has authored 60 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 11 papers in Organic Chemistry and 11 papers in Oncology. Recurrent topics in K. Huber's work include Protein Degradation and Inhibitors (12 papers), Click Chemistry and Applications (7 papers) and Peptidase Inhibition and Analysis (6 papers). K. Huber is often cited by papers focused on Protein Degradation and Inhibitors (12 papers), Click Chemistry and Applications (7 papers) and Peptidase Inhibition and Analysis (6 papers). K. Huber collaborates with scholars based in United Kingdom, Germany and Austria. K. Huber's co-authors include Giulio Superti‐Furga, Franz Bracher, Stefan Knapp, Keiryn L. Bennett, Jacques Colinge, Christelle Gasser, L. Brault, Juerg Schwaller, Manuela Gridling and Johannes W. Bigenzahn and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Angewandte Chemie International Edition.

In The Last Decade

K. Huber

58 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1

2015 506 citations K. Huber, Keiryn L. Bennett et al. profile →

Peers

Countries citing papers authored by K. Huber

Since Specialization

Citations

This map shows the geographic impact of K. Huber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Huber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Huber more than expected).

Fields of papers citing papers by K. Huber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Huber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Huber. The network helps show where K. Huber may publish in the future.

Co-authorship network of co-authors of K. Huber

This figure shows the co-authorship network connecting the top 25 collaborators of K. Huber. A scholar is included among the top collaborators of K. Huber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Huber. K. Huber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells 2025 ·Nature Communications ·(unknown), (unknown), (unknown), Usha Singh, (unknown), James D. Vasta, Michael Beck, Jennifer Wilkinson, Jennifer Ward, Catherine Rogers, (unknown), (unknown), Jesper S. Hansen, P. Loppnau, Adrian Whitty, Paul E. Brennan, Peter J. Tonge, Matthew B. Robers, K. Huber	0
2	Pharmacological targeting of BMAL1 modulates circadian and immune pathways 2025 ·Nature Chemical Biology ·(unknown), (unknown), (unknown), (unknown), Matthew Baxter, K. Huber, Sepideh Khorasanizadeh, David Ray, Fraydoon Rastinejad	8
3	Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Ying Xiong, Anver Basha Shaik, Kiall F. Suazo, (unknown), (unknown), (unknown), K. Huber, (unknown), Rolf E. Swenson, Jordan L. Meier	1
4	Phenomics‐Based Discovery of Novel Orthosteric Choline Kinase Inhibitors 2024 ·Angewandte Chemie International Edition ·(unknown), Jennifer Ward, (unknown), Yvonne Sundström, (unknown), (unknown), Sarantos Kostidis, Catherine Rogers, (unknown), Usha Singh, (unknown), (unknown), H. Ümit Kanıskan, Jianping Hu, Jian Jin, Sonja Sievers, Herbert Waldmann, Martin Giera, (unknown), Louise Berg, K. Huber	0
5	Open resources for chemical probes and their implications for future drug discovery 2023 ·Expert Opinion on Drug Discovery ·(unknown), (unknown), Jesper S. Hansen, K. Huber	4
6	Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3 2023 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), James M. Bennett, Thomas Christott, Matthew Dowling, Gillian Farnie, Oleg Fedorov, (unknown), C. Gileadi, Charline Giroud, K. Huber, Magdalena Korczynska, Chris Limberakis, Arjun Narayanan, Dafydd R. Owen, L. Diaz Saez, Ingrid A. Stock, Allyn T. Londregan	4
7	Discovery of a Chemical Probe to Study Implications of BPTF Bromodomain Inhibition in Cellular and in vivo Experiments 2023 ·ChemMedChem ·Paola Martinelli, Otmar Schaaf, Andreas Mantoulidis, Laetitia J. Martin, Julian E. Fuchs, Gerd Bader, Andreas Gollner, B. Wolkerstorfer, Catherine Rogers, (unknown), Jesse Lipp, Nikolai Mischerikow, (unknown), Thomas Gerstberger, Wolfgang Sommergruber, K. Huber, Jark Böttcher	3
8	Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function 2023 ·Chemical Science ·(unknown), Jessica L. MacDonald, (unknown), Jennifer Ward, Christopher J. Stubbs, Tom E. McAllister, (unknown), (unknown), (unknown), Martine I. Abboud, Yijia Zhang, Hitesh J. Sanganee, K. Huber, Timothy D. W. Claridge, Akane Kawamura	8
9	Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity 2021 ·ChemBioChem ·(unknown), Jennifer Ward, Felix Feyertag, (unknown), (unknown), Kevin M. Guckian, K. Huber, Douglas S. Johnson	6
10	Fragment Screening Reveals Starting Points for Rational Design of Galactokinase 1 Inhibitors to Treat Classic Galactosemia 2021 ·ACS Chemical Biology ·(unknown), T. Krojer, (unknown), L. Diaz Saez, Manshu Tang, K. Huber, F. von Delft, Kent Lai, Paul E. Brennan, G.A. Bezerra, Wyatt W. Yue	9
11	Deliberately Losing Control of C−H Activation Processes in the Design of Small‐Molecule‐Fragment Arrays Targeting Peroxisomal Metabolism 2020 ·ChemMedChem ·(unknown), (unknown), T. Krojer, A.R. Bradley, Srikannathasan Velupillai, R. Talon, M. Fairhead, Iain J. Day, (unknown), Robert Felix, Paul D. Kemmitt, Paul E. Brennan, F. von Delft, L. Diaz Saez, K. Huber, John Spencer	4
12	Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors 2018 ·ACS Chemical Biology ·(unknown), Andrew M. Lewis, Daniel Conole, Sébastien R. G. Galan, Carole J. R. Bataille, Graham M. Wynne, M. Paola Castaldi, Thomas Lundbäck, Angela J. Russell, K. Huber	13
13	IDENTIFICATION OF SMALL MOLECULES TARGETING THE IL-17 INFLAMMATORY PATHWAY BY LABEL-FREE ASSAYS 2018 ·Basic & Clinical Pharmacology & Toxicology ·(unknown), Cristian R. Munteanu, Iria Gómez-Touriño, L. Diaz Saez, K. Huber, (unknown), Eduardo Domínguez	1
14	Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter 2017 ·Scientific Reports ·Branka Radic-Sarikas, Melinda Halász, K. Huber, Georg E. Winter, Kalliopi P. Tsafou, Theodore Papamarkou, Søren Brunak, Walter Kölch, Giulio Superti‐Furga	24
15	Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family 2017 ·Bioorganic & Medicinal Chemistry ·Carole J. R. Bataille, (unknown), Simon Byrne, Stephen G. Davies, Matthew J. Durbin, O. Fedorov, K. Huber, Alan M. Jones, Stefan Knapp, (unknown), (unknown), Camilo Quevedo, Angela J. Russell, (unknown), Robert Westwood, Graham M. Wynne	41
16	Combinatorial Drug Screening Identifies Ewing Sarcoma–specific Sensitivities 2016 ·Molecular Cancer Therapeutics ·Branka Radic-Sarikas, Kalliopi P. Tsafou, Kristina B. Emdal, Theodore Papamarkou, K. Huber, (unknown), Jeffrey A. Toretsky, Keiryn L. Bennett, Jesper V. Olsen, Søren Brunak, Heinrich Kovar, Giulio Superti‐Furga	16
17	Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells 2013 ·Oncology Reports ·Andreas Eisenreich, Andreas Zakrzewicz, K. Huber, (unknown), Wojciech Pepke, Petra Goldin-Lang, Heinz‐Peter Schultheiß, Axel R. Pries, Ursula Rauch	41
18	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma 2013 ·Neoplasia ·Ulrike Weirauch, Nadine Beckmann, Maren Thomas, Arnold Grünweller, K. Huber, Franz Bracher, Roland K. Hartmann, Achim Aigner	85
19	IAU volume 7 issue S282 Cover and Front matter 2011 ·Proceedings of the International Astronomical Union ·T. Montmerle, (unknown), (unknown), J. M. Kreiner, G. Stachowski, (unknown), Zdeněk Mikulášek, Miloslav Zejda, (unknown), K. Huber, Julian Schmitt, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
20	PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers 2010 ·Haematologica ·L. Brault, Christelle Gasser, Franz Bracher, K. Huber, Stefan Knapp, Juerg Schwaller	301

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact